Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript
Cyclacel Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-6.23, expectations were $-6.35.
Cyclacel Pharmaceuticals Inc. (CYCC)
Market is closed
News
- 1 - 10
- Next >>
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Cyclacel Pharmaceuticals Third Quarter 2023 Results Conference Call and Webcast. [Operator Instructions] Please note, today's call is being recorded.
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Cyclacel Pharmaceuticals Second Quarter 2023 Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Cyclacel Pharmaceuticals First Quarter 2023 Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2022 Earnings Call Transcript
Operator: Good afternoon and welcome to the Cyclacel Pharmaceuticals Fourth Quarter and Full Year 2022 Results Conference Call and Webcast. Please note, today's call is being recorded.
10 Popular Penny Stocks on Robinhood
According to the letter acquired by CNBC from Citadel Securities' Institutional Equity Derivatives team, stocks selling below $1 per share recorded an average gain of roughly 80% in June 2020.
Hedge Funds Have Never Been This Bullish On Cyclacel Pharmaceuticals Inc (CYCC)
After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed...
5 Underperforming Stocks Targeted By Short Sellers
In this article we discuss top 5 underperforming stocks targeted by short sellers.
13D Filing: Tang Capital Partners LP and Cyclacel Pharmaceuticals Inc. (CYCC)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240...
Why Cyclacel Pharmaceuticals Inc (CYCC) is in the Spotlight
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) shares have popped over 30% this afternoon due to momentum traders buying the stock for technical reasons.
- 1 - 10
- Next >>
Billionaire Hedge Funds
